Medical

Irish science center AMBER (Advanced Materials and BioEngineering Research), located at Trinity College Dublin, has announced that investigator Anne Marie Healy has received a €600,000 grant from the US National Institutes of Health (NIH) for development of a new mucolytic therapy dry powder inhaler. Clinical trials are expected to begin within five years. … [Read more...] about AMBER announces NIH funding for development of DPI

Mucosis has initiated a Phase 1 study of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. In January 2016, Mucosis announced that it had received a €3.7 million grant from the Wellcome Trust for Phase 1 and Phase 2a studies. The Phase 1 study will be conducted at Imperial College London and will involve 48 healthy adults. The … [Read more...] about Mucosis initiates Phase 1 trial of its intranasal RSV vaccine

Spyryx Biosciences has presented data from preclinical studies of its SPX-101 inhaled SPLUNC1-derived peptide showing that SPX-101 improves mucus clearance and survival in animal models of cystic fibrosis and demonstrated no toxicity. The data were presented in three posters at the North American Cystic Fibrosis Conference. According to the company, nebulized … [Read more...] about Spyryx Biosciences presents data from preclinical studies of SPX-101

Arch Biopartners has announced that Dr. Ralph Panos of the Cincinnati Veterans Affairs Medical Center (CVAMC) will prepare a protocol for human trials of the company's AB569 inhaled bactericide and will subsequently prepare an application to conduct the trials. The company expects that the application will be submitted to the IRB of the CVAMC by December 2016, … [Read more...] about Arch Biopartners announces preparations for Phase 1 and 2 trials of AB569

Upsher-Smith Laboratories has presented data from a Phase 1 study of its USL261 midazolam nasal spray in children with epilepsy demonstrating that the median Tmax for 1.25 mg, 2.5 mg and 5 mg single doses was ~15 minutes and Cmax was not dose dependent. According to the company, the FDA has granted both fast track and orphan drug designations to USL261 for rescue … [Read more...] about Upsher-Smith reports results from Phase 1 study of midazolam nasal spray in children

Windtree Therapeutics has announced that a lung deposition study in cynomolgus macaques showed that its proprietary aerosol delivery system (ADS) delivered KL4 surfactant uniformly to all regions of the lung. The ADS is being developed to deliver Windtree's Aerosurf inhaled lucinactant, which is in Phase 2 development for the treatment of respiratory distress syndrome … [Read more...] about Windtree Therapeutics announces data from deposition study using its aerosol delivery system

Eurocine Vaccines has started a Phase 1/2 clinical study of its Immunose FLU intranasal quadrivalent influenza vaccine, which uses the company's Endocine adjuvent and inactivated split antigens, the company said. Results should be available in mid-2017. Eurocine Vaccines Chief Scientific Officer Anna-Karin Maltais said, "We are very pleased that our nasal influenza … [Read more...] about Eurocine Vaccines begins Phase 1/2 study of intranasal flu vaccine

Sunovion Pharmaceuticals and the American College of Chest Physicians (CHEST) have launched an initiative called "Delivery Makes a Difference," which they say "seeks to understand patient and health care provider practices and to provide tools for matching patients with appropriate medications and delivery devices." According to the announcement, a steering … [Read more...] about Sunovion partners with CHEST for “Delivery Makes a Difference” initiative

Theravance Biopharma and Mylan have announced that two 12-week Phase 3 efficacy studies of nebulized revefenacin (TD-4208) for the treatment of COPD have met their primary efficacy endpoint of statistically significant increase in FEV1 for both doses studied compared to placebo. Patients receiving the 88 mcg dose averaged a 118 mL increase in tough FEV1 after 12 weeks … [Read more...] about Mylan and Theravance announce positive Phase 3 results for inhaled revefenacin for COPD

Aradigm Corporation has partnered with Professors Daniela Traini and Paul Young of the University of Sydney's Woolcock Institute of Medical Research to develop an aerosol nanoparticle technology to combat fungal and bacterial biofilms. The project will be funded by a A$420,000 grant from an Australian Research Council Linkage Project over three years. According to … [Read more...] about Aradigm and Woolcock Institute of Medical Research get grant for development of aerosol nanotechnology